Evelyn D’An Joins Cytovia Therapeutics as Chief Financial Officer AVENTURA, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc. (“Cytovia”), a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited iNK and CAR (Chimeric Antigen...

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline Cytovia eligible for up to $400 million in licensing milestones for Greater China rightsCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma AVENTURA,...